Information Provided By: 
Fly News Breaks for October 31, 2019
ABMD
Oct 31, 2019 | 16:30 EDT
Piper Jaffray analyst Matt O'Brien views Abiomed's Q2 results as a "relief" and keeps an Overweight rating on the shares with a $240 price target. Some investors may question the company's ability to meet the low end of its guidance given the large sequential increases factored in, O'Brien tells investors in a research note. However, he believes these levels "seem attainable" with the resurgence of RP, the 5.5 controlled rollout, and an expanded salesforce.
News For ABMD From the Last 2 Days
There are no results for your query ABMD
